Cytokines and chemokines in immune-based ocular surface inflammation

Expert Review of Clinical Immunology

Volumn 4, Issue 4, 2008, Pages 457-467

  Enríquez de Salamanca, Amalia ^a,b   Calonge, Margarita ^a,b  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Chemokine; Cytokine; Dry eye syndrome; Inflammation; Ocular chronic allergy

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; CHEMOKINE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1 ANTAGONIST; CHEMOKINE RECEPTOR CCR3 ANTAGONIST; CYCLOSPORIN; CYTOKINE; CYTOKINE ANTIBODY; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; INFLIXIMAB; OLOPATADINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; SUPPRESSOR OF CYTOKINE SIGNALING 5; TRANILAST;

ALLERGIC CONJUNCTIVITIS; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG MECHANISM; DRY EYE; EPITHELIUM CELL; EYE ALLERGY; EYE INFLAMMATION; HUMAN; IMMUNOPATHOGENESIS; MEDIATOR RELEASE; MUCOSA INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW;

EID: 46149121515     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.4.4.457     Document Type: Review

References (87)

1. Calonge M. Classification of ocular atopic/allergic disorders and conditions: an unsolved problem. Acta Ophthalmol. Scand. 228(Suppl.), 10-13 (1999).
2. Pflugfelder SC. Anti-inflammatory therapy of dry eye. Ocul. Surf. 1(1), 31-36 (2003).
3. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 17(6), 584-589 (1998).
4. Dinarello CA. Historical insights into cytokines. Eur. J. Immunol. 37(Suppl. 1), S34-S45 (2007).
5. Stern ME, Siemasko K, Gao J et al. Role of interferon-γ in a mouse model of allergic conjunctivitis. Invest. Ophthalmol. Vis. Sci. 46(9), 3239-3246 (2005).
6. Stern ME, Siemasko KF, Niederkorn JY. The Th1/Th2 paradigm in ocular allergy. Curr. Opin. Allergy Clin. Immunol. 5(5), 446-450 (2005).
7. Leonardi A, Fregona IA, Plebani M, Secchi AG, Calder VL. Thl- and Th2- type cytokines in chronic ocular allergy. Graefes Arch. Clin. Exp. Ophthalmol. 244(10), 1240-1245 (2006).
8. Leonardi A, De Dominicis C, Motterle L. Immunopathogenesis of ocular allergy. a schematic approach to different clinical entities. Curr. Opin. Allergy Clin. Immunol. 7(5), 429-435 (2007).
9. Pease JE, Williams TJ. Chemokines and their receptors in allergic disease. J. Allergy Clin. Immunol. 118(2), 305-318 (2006).
10. D'Ambrosio D, Panina-Bordignon P, Sinigaglia F. Chemokine receptors in inflammation: an overview. J. Immunol. Methods 273(1-2), 3-13 (2003).
11. Calder VL, Lackie PM. Basic science and pathophysiology of ocular allergy. Curr. Allergy Asthma Rep. 4(4), 326-331 (2004).
12. Stahl JL, Barney NP. Ocular allergic disease. Curr. Opin. Allergy. Clin. Immunol. 4(5), 455-459 (2004).
13. Calder VL, Jolly G, Hingorani M et al. Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. Clin. Exp. Allergy 29 (9), 1214-1222 (1999).
14. Hingorani M, Calder V, Jolly G, Buckley RJ, Lightman SL. Eosinophil surface antigen expression and cytokine production vary in different ocular allergic diseases. J. Allergy Clin. Immunol. 102(5), 821-830 (1998).
15. Hingorani M, Calder VL, Buckley RJ, Lightman SL. The role of conjunctival epithelial cells in chronic ocular allergic disease. Exp. Eye Res. 67(5), 491-500 (1998).
16. Bisset LR, Schmid-Grendelmeier P. Chemokines and their receptors in the pathogenesis of allergic asthma: progress and perspective. Curr. Opin. Pulm. Med. 11(1), 35-42 (2005).
17. Pease JE. Asthma, allergy and chemokines. Curr. Drug Targets 7(1), 3-12 (2006).
18. Davies DE, Holgate ST. Asthma: the importance of epithelial mesenchymal communication in pathogenesis. Inflammation and the airway epithelium in asthma. Int. J. Biochem. Cell Biol. 34(12), 1520-1526 (2002).
19. Holgate ST, Davies DE, Lackie PM, Wilson SJ, Puddicombe SM, Lordan JL. Epithelial-mesenchymal interactions in the pathogenesis of asthma. J. Allergy Clin. Immunol. 105(2 Pt 1), 193-204 (2000).
20. Diebold Y, Calonge M, Carretero V, Fernandez N, Herreras JM. Expression of ICAM-1 and HLA-DR by human conjunctival epithelial cultured cells and modulation by nedocromil sodium. J. Ocul. Pharmacol. Ther. 14(6), 517-531 (1998).
21. Irkec M, Bozkurt B. Epithelial cells in ocular allergy. Curr. Allergy Asthma Rep. 3(4), 352-357 (2003).
22. Zhan H, Towler HM, Calder VL. The immunomodulatory role of human conjunctival epithelial cells. Invest. Qphthalmol. Vis. Sci. 44(9), 3906-3910 (2003).
23. Diebold Y, Calonge M, Enriquez de Salamanca A et al. Characterization of a spontaneously immortalized cell line (IOBA-NHC) from normal human conjunctiva. Invest. Ophthalmol. Vis. Sci. 44(10), 4263-4274 (2003).
24. Gao J, Siemasko KF, Diebold Y et al. In vitro models of ocular inflammation using normal conjunctival cells. Invest. Ophthalmol. Vis. Sci. 44, E-abstract 683 (2003).
25. Stahl JL, Cook EB, Graziano FM, Barney NP. Differential and cooperative effects of TNF α, IL-1β, and IFN γ on human conjunctival epithelial cell receptor expression and chemokine release. Invest. Ophthabnol. Vis. Sci. 44(5), 2010-2015 (2003).
26. Calonge M, Enriquez-de-Salamanca A. The role of the conjunctival epithelium in ocular allergy. Curr. Opin. Allergy Clin. Immunol. 5(5), 441-445 (2005).
27. Siemasko KF, Gao J, Enriquez-de-Salamanca A. Inflammatory cytokine effects on co-stimulatory molecule and chemokines expression in the human conjunctival epithelial cell line, IOBA-NHC. Invest. Ophthalmol. Vis. Sci. 46, E-abstract 2687 (2005).
28. Enríquez de Salamanca A, Siemasko KF, Diebold Y et al. Expression of muscarinic and adrenergic receptors in normal human conjunctival epithelium. Invest. Ophthalmol. Vis. Sci. 46(2), 504-513 (2005).
29. Motterle L, Diebold Y, Enriquez de Salamanca A et al. Altered expression of neurotransmitter receptors and neuromediators in vernal keratoconjunctivitis. Arch. Ophthalmol. 124(4), 462-468 (2006).
30. Calonge M, De Salamanca AE, Siemasko KF et al. Variation in the expression of inflammatory markers and neuroreceptors in human conjunctival epithelial cells. Ocul. Surf. 3(4 Suppl.), S145-S148 (2005).
31. Enríquez-de-Salamanca A, Gao J, Calder V et al. Cytokine/ chemokine secretion by human conjunctival epithelial cells stimulated with Th1- or Th2-derived cytokines. Invest. Ophthalmol. Vis. Sci. 47, E-abstract 4937 (2006).
32. Calonge M, Enríquez-de-Salamanca A, Garcia-Vazquez C, Stern ME. Specific patterns of conjunctival epithelial barrier alteration induced by Th1 versus Th2 cytokines. Invest. Ophthalmol. Vis. Sci. 47, 4938 (2006) (E-abstract).
33. Kumagai N, Fukuda K, Fujitsu Y, Yamamoto K, Nishida T. Role of structural cells of the cornea and conjunctiva in the pathogenesis of vernal keratoconjunctivitis. Prog. Retin. Eye Res. 25(2), 165-187 (2006).
34. Fukagawa K, Nakajima T, Tsubota K, Shimmura S, Saito H, Hirai K. Presence of eotaxin in tears of patients with atopic keratoconjunctivitis with severe corneal damage. J. Allergy Clin. Immunol. 103(6), 1220-1221 (1999).
35. Leonardi A, Jose PJ, Zhan H, Calder VL. Tear and mucus cotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. Ophthalmology 110(3), 487-492 (2003).
36. Fukuda K, Fujitsu Y, Seki K, Kumagai N, Nishida T. Differential expression of thymus- and activation-regulated chemokine (CCL17) and macrophage-derived chemokine (CCL22) by human fibroblasts from cornea, skin, and lung. J. Allergy Clin. Immunol. 111(3), 520-526 (2003).
37. Fukuda K, Kumagai N, Fujitsu Y, Nishida T. Fibroblasts as local immune modulators in ocular allergic disease. Allergol. Int. 55(2), 121-129 (2006).
38. Uchio E, Ono SY, Ikezawa Z, Ohno S. Tear levels of interferon-γ, interleukin (IL)-2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. Clin. Exp. Allergy 30(1), 103-109 (2000).
39. Sack R, Conradi L, Beaton A, Sathe S, McNamara N, Leonardi A. Antibody array characterization of inflammatory mediators in allergic and normal tears in the open and closed eye environments. Exp. Eye Res. 85(4), 528-538 (2007).
40. Shoji J, Inada N, Sawa M. Antibody array-generated cytokine profiles of tears of patients with vernal keratoconjunctivitis or giant papillary conjunctivitis. Jpn. J. Ophthalmol. 50(3), 195-204 (2006).
41. Shoji J, Kawaguchi A, Gotoh A, Inada N, Sawa M. Concentration of soluble interleukin-6 receptors in tears of allergic conjunctival disease patients. Jpn. J. Ophthalmol. 51(5), 332-337 (2007).
42. Cook EB, Stahl JL, Lowe L et al. Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. J. Immunol. Methods 254(1-2), 109-118 (2001).
43. Cook EB. Tear cytokines in acute and chronic ocular allergic inflammation. Curr. Opin. Allergy Clin. Immunol. 4(5), 441-445 (2004).
44. Nivenius E, Montan PG, Chryssanthou E, Jung K, van Hage-Hamsten M, van der Ploeg I. No apparent association between periocular and ocular microcolonization and the degree of inflammation in patients with atopic keratoconjunctivitis. Clin. Exp. Allergy 34(5), 725-730 (2004).
45. Leonardi A, Curnow J, Calder VL. Multiple cytokine evaluation in tears of allergic conjunctivitis patients by multiple-cytokine bead assay. Invest. Ophthalmol. Vis. Sci. 45, E-abstract 625 (2004).
46. Sarac O, Erdener U, Irkec M, Us D, Gungen Y. Tear eotaxin levels in giant papillary conjunctivitis associated with ocular prosthesis. Ocul. Immunol. Inflamm. 11(3), 223-230 (2003).
47. Leonardi A, Curnow SJ, Zhan H, Calder VL. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin. Exp. Allergy 36(6), 777-784 (2006).
48. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul. Surf. 5 (2), 75-92 (2007).
49. Stern ME, Gao J, Siemasko KF, Beuerman RW, Pflugfelder SC. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp. Eye Res. 78(3), 409-416 (2004).
50. Pflugfelder SC, Beuerman RW, Stern ME. Dry Eye and Ocular Surface Disorders. Marcel Dekker, Informa Healthcare, London, UK (2004).
51. Jones DT, Monroy D, Ji Z, Atherton SS, Pflugfeldcr SC. Sjogren's syndrome: cytokine and Epstein-Barr viral gene expression within the conjunctival epithelium. Invest. Qphthalmol. Vis. Sci. 35(9), 3493-3504 (1994).
52. Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogren's syndrome keratoconjunctivitis sicca. Curr. Eye Res. 19(3), 201-211 (1999).
53. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest. Qphthalmol. Vis. Sci. 42(10), 2283-2292 (2001).
54. Tishler M, Yaron I, Geyer O, Shirazi I, Naftaliev E, Yaron M. Elevated tear interleukin-6 levels in patients with Sjogren syndrome. Ophthalmology 105(12), 2327-2329 (1998).
55. Yoon KC, Jeong IY, Park YG, Yang SY. Interleukin-6 and tumor necrosis factor-α levels in tears of patients with dry eye syndrome. Cornea 26(4), 431-437 (2007).
56. Corrales RM, Villarreal A, Farley W, Stern ME, Li DQ, Pflugfelder SC. Strain-related cytokine profiles on the murine ocular surface in response to desiccating stress. Cornea 26(5), 579-584 (2007).
57. Gorham JD, Guler ML, Steen RG et al. Genetic mapping of a murine locus controlling development of T helper 1/T helper 2 type responses. Proc. Natl Acad. Sci. USA 93(22), 12467-12472 (1996).
58. Yoon KC, De Paiva CS, Qi H et al. Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6 mice: effects of desiccating stress. Invest. Qphthalmol. Vis. Sci. 48(6), 2561-2569 (2007).
59. Narayanan S, Miller WI, McDermott AM. Conjunctival cytokine expression in symptomatic moderate dry eye subjects. Invest. Qphthalmol. Vis. Sci. 47(6), 2445-2450 (2006).
60. Wong EK, Dang QN, Siemasko K et al. Cytokine study of the denervated rat model of dry eye. Invest. Ophthalmol. Vis. Sci. 49, 334 (2008) (E-abstract).
61. De Paiva CS, Chotikavanich S, Pangelinan S et al. Desiccating stress promotes Th-17 pattern response in the conjuntiva. Invest. Ophthalmol. Vis. Sci. 49, E-abstract 5420 (2008).
62. Pflugfelder SC, Stern ME. Future directions in therapeutic interventions for conjunctival inflammatory disorders. Curr. Opin. Allergy Clin. Immunol. 7(5), 450-453 (2007).
63. Elliott J, Johnston JA. SOCS: role in inflammation, allergy and homeostasis. Trends Immunol. 25(8), 434-440 (2004).
64. Hebenstreit D, Luft P, Schmiedlechner A, Duschl A, Horejs-Hoeck J. SOCS-1 and SOCS-3 inhibit IL-4 and IL-13 induced activation of eotaxin-3/ CCL26 gene expression in HEK293 cells. Mol. Immunol. 42(3), 295-303 (2005).
65. Seki Y, Inoue H, Nagata N et al. SOCS-3 regulates onset and maintenance of Th2-mediated allergic responses. Nat. Med. 9(8), 1047-1054 (2003).
66. Horiuchi Y, Bae SJ, Katayama I. Overexpression of the suppressor of cytokine signalling 3 (SOCS3) in severe atopic dermatitis. Clin. Exp. Dermatol. 31(1), 100-104 (2006).
67. Ozaki A, Seki Y, Fukushima A, Kubo M. The control of allergic conjunctivitis by suppressor of cytokine signaling (SOCS)3 and SOCS5 in a murine model. J. Immunol. 175(8), 5489-5497 (2005).
68. Kubo M, Ozaki A, Tanaka S, Okamoto M, Fukushima A. Role of suppressor of cytokine signaling in ocular allergy. Curr. Opin. Allergy Clin. Immunol. 6(5), 361-366 (2006).
69. Shen HH, Xu F, Zhang GS, Wang SB, Xu WH. CCR3 monoclonal antibody inhibits airway eosinophilic inflammation and mucus overproduction in a mouse model of asthma. Acta Pharmacol. Sin. 27(12), 1594-1599 (2006).
70. Wegmann M, Goggel R, Sel S et al. Effects of a low-molecular-weight CCR-3 antagonist on chronic experimental asthma. Am. J. Respir. Cell Mol. Biol. 36(1), 61-67 (2007).
71. Wang K, Shen HH, Li W, Huang HQ. Human C-C chemokine receptor 3 monoclonal antibody inhibits pulmonary inflammation in allergic mice. Acta Pharmacol. Sin. 28(11), 1791-1796 (2007).
72. Fukagawa K, Okada N, Fujishima H et al. CC-chemokine receptor 3: a possible target in treatment of allergy-related corneal ulcer. Invest. Ophthalmol. Vis. Sci. 43(1), 58-62 (2002).
73. Gulati A, Sacchetti M, Bonini S, Dana R. Chemokine receptor CCR5 expression in conjunctival epithelium of patients with dry eye syndrome. Arch. Ophthalmol. 124(5), 710-716 (2006).
74. Hida RY, Takano Y, Okada N et al. Suppressive effects of tranilast on eotaxin-1 production from cultured conjunctival fibroblasts. Curr. Eye Res. 33(1), 19-22 (2008).
75. Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits TNFα release from human conjunctival mast cells. Ann. Allergy Asthma Immunol. 84(5), 504-508 (2000).
76. Cook EB, Stahl JL, Brooks AM, Graziano FM, Barney NP. Allergic tears promote upregulation of eosinophil adhesion to conjunctival epithelial cells in an ex vivo model: inhibition with olopatadine treatment. Invest. Ophthalmol. Vis. Sci. 47(8), 3423-3429 (2006).
77. Cook EB, Stahl JL, Sedgwick JB, Barney NP, Graziano FM. The promotion of eosinophil degranulation and adhesion to conjunctival epithelial cells by IgE-activated conjunctival mast cells. Ann. Allergy Asthma Immunol. 92(1), 65-72 (2004).
78. Galatowicz G, Ajayi Y, Stern ME, Calder VL. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo. Clin. Exp. Allergy 37(11), 1648-1656 (2007).
79. Pauly A, Brignole-Baudouin F, Guenoun JM et al. Comparative study of topical anti-allergic eye drops on human conjunctiva-derived cells: responses to histamine and IFN γ and toxicological profiles. Graefes Arch. Clin. Exp. Ophthalmol. 245(4), 534-546 (2007).
80. Pflugfelder SC, De Paiva CS, Villarreal AL, Stern ME. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-β2 production. Cornea 27(1), 64-69 (2008).
81. Steinfeld SD, Demols P, Appelboom T. Infliximab in primary Sjogren's syndrome: one-year followup. Arthritis Rheum. 46(12), 3301-3303 (2002).
82. Mariette X, Ravaud P. Steinfeld S et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum. 50(4), 1270-1276 (2004).
83. Sankar V, Brennan MT, Kok MR et al. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 50(7), 2240-2245 (2004).
84. Zandbelt MM, de Wilde P, van DP, Hoyng CB, van de Putte L, van den Hogen F. Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study. J. Rheumatol. 31(1), 96-101 (2004).
85. Narayanan S, Glasser A, Hu YS, McDermott AM. The effect of interleukin-1 on cytokine gene expression by human corneal epithelial cells. Exp. Eye Res. 80(2), 175-183 (2005).
86. Kalliolias GD, Liossis SN. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Exp. Opin. Investig. Drugs 17(3), 349-359 (2008).
87. Keane-Myers AM, Miyazaki D, Liu G, Dekaris I, Ono S, Dana MR. Prevention of allergic eye disease by treatment with IL-1 receptor antagonist. Invest. Ophthalmol. Vis. Sci. 40(12), 3041-3046 (1999).